Trapero-Quintana YM, Gonzáles-Delgado CA, Olivera-Ruano L, Correa A

Language: Spanish
References: 12
Page: 5-9
PDF size: 60.05 Kb.

ABSTRACT

The 4-hydroxy-3-metoxybenzaldehyde (vanillin) candidate agent for Sickle Cell Disease, a disease for which effective treatment doesn’t exist. It is necessary to develop preclinical studies of this made up with a formulation that guarantees its bioavailability. The references of the toxicological studies of 4-hydroxy-3-metoxybenzaldehyde only report its administration like component of the animal diet, reason why it is not safe to calculate the really absorbed quantity and the one wasted. It should be carried out a preformulation study looking for the vehicle that favors a better absorption and that you can use in the preclinical studies, through the oral administration for gastric intubation. We were studied three formulations (0.5% carboxymethylcelulose, 2% carboxymethylcelulose and 15% hydroalcoholic solution as reference) in Wistar rats. The purpose was to looking for the most appropriate for the toxicological studies of vanillin. We determined some pharmacokinetics parameters (ABCtotal, Cmax, tmax, t½, MRT, Tlag, Frel) of the three formulations. The 0.5% carboxymethylcelulose was selected because it offered the plasmatic levels that guarantee an appropriate exhibition level, determined using an analytic method for high performance liquid chromatography (HPLC), validated in the National Center of Toxicology.

REFERENCES

1. Serjeant GR. Sickle cell disease. 2nd ed. Oxford: University Press; 1992: 56, 61, 71-77, 120-366.

2. Colombo B, Guerchicoff E, Martínez G. Genética y clínica de las hemoglobinas humanas. La Habana: Editorial Pueblo y Educación; 1993: 146-195.

3. Espinosa E. La anemia drepanocítica en Cuba. Experiencia de 30 años. Rev Cubana Hematol Inmunol Hemot. 1996; 12: 97-105.

4. Govin AT, Fernández AA, Navarro ZR. Sicklemia. Atención integral y repercusión social. V Conferencia Internacional Cultura Africana y Afroamericana. Santiago de Cuba: 1998.

5. Del Toro G, Falcón JE, Alonso Y, Valdés YC, Cabal CA. Vainillina: agente inhibidor de la polimerización de la hemoglobina. S Bioquimia. 2003; 28: 4-10.

6. Del Toro G, Valdés YC, de la Rosa MC, Falcón V, Cabal CA. Actividad antidrepanocítica de la vainillina sobre hematíes de un paciente con drepanocitemia por microscopía electrónica de transmisión. Bioquimia. 2004; 29: 5-10.

7. Aruoma OI. Dietary management of sickle cell anemia with vanillin. Free Radic Res Commun. 1992; 17: 349-352.

8. Zhang CH, Li X, Lian L, Chen Q, Abdulmalik O, et al . Antisickling effect of MX-1520, a prodrug of vanillin: an in vivo study using rodents. Br J Haematol. 2004; 125: 788-795.

9. Castel-Branco MM, Cayen MN. Considerations in the design of toxicokinetic programs. Toxicol Pathol. 1995; 23: 148-157.

10. Guidelines for breeding and care of laboratory animals. World Health organization and International Council for Laboratory Animals Science (ICLAS). 1998.

11. Food and Drug Administration. Good laboratory practice for non clinical laboratory studies. Title 21 code of federal regulations subchapter A, 1997 (Pt 58).

12. Trapero YM, Gonzáles CA, Olivera L. Estudio farmacocinético del 4-hidroxi-3-metoxibenzaldehído en perros beagles por vía oral. Rev Cubana Farm. 2002; 36 (Suppl. 1).